Pharmacology

Handbook of Clinical Neurology

Volumn 97, Issue C, 2010, Pages 47-71

  Bolay, Hayrunnisa ^a   Durham, Paul ^b  

^a GAZI UNIVERSITY   (Turkey)

^b MISSOURI STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN; SEROTONIN AGONIST; TRYPTAMINE DERIVATIVE;

HUMAN; MIGRAINE;

ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; MIGRAINE DISORDERS; SEROTONIN; SEROTONIN RECEPTOR AGONISTS; TRYPTAMINES;

EID: 77956290415     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(10)97004-8     Document Type: Book

References (256)

1. Adham N., Borden L.A., Schechter L.E., et al. Cell-specific coupling of the cloned human 5-HT1F receptor to multiple signal transduction pathways. Naunyn Schmiedebergs Arch Pharmacol 1993, 348:566-575.
2. Adly C., Straumanis J., Chesson A. Fluoxetine prophylaxis of migraine. Headache 1992, 32:101-104.
3. 2 selectively blocks inhibitory glycinergic neurotransmission onto rat superficial dorsal horn neurons. Nat Neurosci 2002, 5:34-40.
4. Ahn A., Basbaum A. Tissue injury regulates serotonin 1D receptor expression: implications for the control of migraine and inflammatory pain. J Neurosci 2006, 26:8332-8338.
5. Akcali D.T., Doganay-Aydin H., Bolay H. Metoclopramide inhibits trigeminovascular activation: evidence for effective acute attack treatment in migraine. Cephalalgia 2008, 28:464.
6. Alemdar M., Akman O., Selekler H., et al. Does metoprolol inhibit the cortical spreading depression? Acute effects of systematic metropol on CSD in rats. Cephalalgia 2007, 27:1010-1013.
7. Amara S., Arriza J., Leff S., et al. Expression in brain of a messenger RNA encoding a novel neuropeptide homologous to calcitonin gene-related peptide. Science 1985, 229:1094-1097.
8. Antonaci F., Costa A., Candeloro E., et al. Single high-dose steroid treatment in episodic cluster headache. Cephalalgia 2005, 25:290-295.
9. 2. Am J Physiol 1999, 277:H924-H930.
10. Ayajiki K., Okamura T., Toda N. Flunarizine, an anti-migraine agent, impairs nitroxidergic nerve function in cerebral arteries. Eur J Pharmacol 1997, 329:49-53.
11. Ayata C., Jin H., Kudo C., et al. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 2006, 59:652-661.
12. 2. J Neurosci 2001, 21:1750-1756.
13. 2 enzymes present in P388D1 macrophages. J Biol Chem 1996, 271:6758-6765.
14. Barnes N., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999, 38:1083-1152.
15. Beattie D., Connor H. The pre- and postjunctional activity of CP-122,288, a conformationally restricted analogue of sumatriptan. Eur J Pharmacol 1995, 276:271-276.
16. Bendtsen L., Jensen R. Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. Neurology 2004, 62:1706-1711.
17. Bjorkman R. Central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol. Experimental studies in the rat. Acta Anaesthesiol Scand Suppl 1995, 103:1-44.
18. Blier P. Terminal serotonin autoreceptor function in the rat hippocampus is not modified by pertussis and cholera toxins. Naunyn Schmiedebergs Arch Pharmacol 1991, 344:160-166.
19. Boess F., Martin I. Molecular biology of 5-HT receptors. Neuropharmacology 1994, 33:275-317.
20. Bolay H., Moskowitz M.A. Mechanism of pain modulation in chronic syndromes. Neurology 2002, 59(Suppl. 2):S2-S7.
21. Bolay H., Moskowitz M. The emerging importance of cortical spreading depression in migraine headache. Rev Neurol 2005, 161:655-657.
22. Bolay H., Reuter U., Dunn A.K., et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 2002, 8:136-142.
23. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000, 343:1520-1528.
24. Botting R. Mechanism of action of acetaminophen: Is there a cylooxygenase 3?. Clin Infect Dis 2000, 31:S202-S210.
25. Botting R. COX-1 and COX-3 inhibitors. Thromb Res 2003, 110:269-272.
26. Bouchelet I., Cohen Z., Casae B., et al. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol Pharmacol 1996, 50:219-223.
27. Brain S., Williams T., Tippins J.R., et al. Calcitonin gene-related peptide is a potent vasodilator. Nature 1985, 313:54-56.
28. Brede M., Philipp M., Knaus A., et al. Alpha2-adrenergic receptor subtypes - novel functions uncovered in gene-targeted mouse models. Biol Cell 2004, 96:343-348.
29. Bresalier R.S., Sandler R.S., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352:1092-1102.
30. Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain 2001, 89:107-110.
31. Burstein R., Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol 2004, 55:27-36.
32. Burstein R., Yarnitsky D., Goor-Areyh I. An association between migraine and cutaneous allodynia. Ann Neurol 2000, 47:614-624.
33. Burstein R., Collins B., Jakubowski M., et al. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004, 55:19-26.
34. Buzzi M.G., Sakas D.E., Moskowitz M.A. Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater. Eur J Pharmacol 1989, 165:251-258.
35. Buzzi M., Carter W., Shimizu T., et al. Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior saggital sinus during electrical stimulation of the trigeminal ganglia. Neuropharmacology 1991, 30:1193-1200.
36. Buzzi M.G., Dimitriadou V., Theoharides T.C., et al. 5-Hydroxytryptamine receptor agonists for the abortive treatment of vascular headaches block mast cell, endothelial and platelet activation within the rat dura mater after trigeminal stimulation. Brain Res 1992, 583:137-149.
37. Buzzi M., Bonamini M., Moskowitz M., et al. Neurogenic model of migraine. Cephalalgia 1995, 15:277-280.
38. Calabresi P., Galletti F., Rossi C., et al. Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms. Trends Pharmacol Sci 2007, 28:188-195.
39. Cavazos J.E., Caress J.B., Chilukuri V.R., et al. Sumatriptan-induced stroke in sagittal sinus thrombosis. Lancet 1994, 343:1105-1106.
40. Chandrasekharan N.V., Dai H., Roos K.L., et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002, 99:13926-13931.
41. Chiba T., Yamaguchi A., Yamatani T., et al. Calcitonin gene-related peptide receptor antagonist human CGRP-(8-37). Am J Physiol 1989, 256:E331-E335.
42. Chizh B.A., Illes P. P2X receptors and nociception. Pharmacol Rev 2001, 53:553-568.
43. Couch J.R., Hassanein R.S. Amitriptyline in migraine prophylaxis. Arch Neurol 1979, 36:695-699.
44. Cumberbatch M., Hill R., Hargreaves R.J., et al. Rizatriptan has central antinociceptive effects against durally evoked responses. Eur J Pharmacol 1997, 328:37-40.
45. Cumberbatch M., Hill R., Hargreaves R.J., et al. The effects of 5-HT1A, 5-HT1B and 5-HT1D receptor agonists on trigeminal nociceptive neurotransmission in anaesthetized rats. Eur J Pharmacol 1998, 362:43-46.
46. Cutrer F.M., Limmroth V., Ayata G., et al. Attenuation by valproate of c-fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin. Br J Pharmacol 1995, 116:3199-3204.
47. D'Andrea G., Nordera G.P., Perini F., et al. Biochemistry of neuromodulation in primary headaches: focus on anomalies of tyrosine metabolism. Neurol Sci 2007, 28(Suppl. 2):S94-S96.
48. Davis R.J., Murdoch C.E., Ali M., et al. EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries. Br J Pharmacol 2004, 141:580-585.
49. De Fusco M., Marconi R., Silvestri L., et al. Haploinsufficiency of ATP1A2 encoding the Na-,K-pump -2 subunit gene is responsible for familial hemiplegic migraine type 2. Nat Genet 2003, 33:192-196.
50. Dichgans M., Freilinger T., Eckstein G., et al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet 2005, 366:371-377.
51. Dick I.E., Brochu R.M., Purohit Y., et al. Sodium channel blockade may contribute to the analgesic efficacy of antidepressants. J Pain 2007, 8:315-324.
52. Diener H.C., Lampl C., Reimnitz P., et al. Aspirin in the treatment of acute migraine attacks. Expert Rev Neurother 2006, 6:563-573.
53. Dimitriadou V., Buzzi M.G., Theoharides T.C., et al. Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation. Neuroscience 1992, 48:187-203.
54. Doods H., Hallermayer G., Wu D., et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 2000, 129:420-423.
55. Durham P., Russo A. Serotonergic repression of mitogen-activated protein kinase control of the calcitonin gene-related peptide enhancer. Mol Endocrinol 1998, 12:1002-1009.
56. Durham P.L., Russo A.F. New insights into the molecular actions of serotonergic antimigraine drugs. Pharmacol Ther 2002, 94:77-92.
57. Durham P., Sharma R., Russo A.F., et al. Repression of the calcitonin gene-related peptide promoter by 5-HT1 receptor activation. J Neurosci 1997, 17:9545-9553.
58. Durham P.L., Cady R., Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004, 44:35-43.
59. 2 from rat dura mater encephali following electrical and chemical stimulation in vitro. Neuroscience 1999, 89:901-907.
60. Edvinsson L., Goadsby P. Neuropeptides in migraine and cluster headache. Cephalalgia 1994, 14:320-327.
61. Evers S., Afra J., Frese A., et al. EFNS guideline on the drug treatment of migraine - report of an EFNS task force. Eur J Neurol 2006, 13:560-572.
62. Fanciullacci M., Alessandri M., Figini M., et al. Increase in plasma calcitonin gene-related peptide from the extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain 1995, 60:119-123.
63. Ferrari M.D. Migraine. Lancet 1998, 351:1043-1051.
64. Ferrari M., Saxena P. On serotonin and migraine: a clinical and pharmacological review. Cephalalgia 1993, 13:151-165.
65. Ferrari M., Roon K., Lipton R.B., et al. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001, 358:1668-1675.
66. Fischer J., Born W. Novel peptides from the calcitonin gene: expression, receptors and biological function. Peptides 1985, 6:265-271.
67. Friberg L., Olesen J., Iversen H.K., et al. Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan. Lancet 1991, 338:13-17.
68. Fumal A., Schoenen J. Current migraine management - patient acceptability and future approaches. Neuropsychiatr Dis Treat 2008, 4:1043-1057.
69. Galeotti N., Ghelardini C., Bartolini A. Involvement of potassium channels in amitriptyline and clomipramine analgesia. Neuropharmacology 2001, 40:75-84.
70. Garavito R.M., Dewitt D.L. The cyclooxygenase isoforms: structural insights into the conversion of arachidonic acid to prostaglandins. Biochim Biophys Acta 1999, 1441:278-287.
71. Gaspar P., Berger B., Febvret A., et al. Catecholamine innervation of the human cerebral cortex as revealed by comparative immunohistochemistry of tyrosine hydroxylase and dopamine-beta-hydroxylase. J Comp Neurol 2004, 279:249-271.
72. Geraud G., Keywood C., Senard J.M., et al. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 2003, 43:376-388.
73. Giffin J.J., Kowacs F., Libri V., et al. Effect of the adenosine A1 receptor agonist GR79236 on trigeminal nociception with blink reflex recording in healthy human subjects. Cephalalgia 2003, 23:287-292.
74. Goadsby P., Edvinsson L. Sumatriptan reverses the changes in calcitonin gene-related peptide seen in the headache phase of migraine. Cephalalgia 1991, 11:3-4.
75. Goadsby P., Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993, 33:48-56.
76. Goadsby P., Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain 1994, 117:427-434.
77. Goadsby P., Edvinsson L. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache 1994, 34:394-399.
78. Goadsby P.J., Hoskin K.L. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine?. Pain 1996, 67:355-359.
79. Goadsby P., Lipton R., Ferrari M., et al. Migraine - current understanding and treatment. N Engl J Med 2002, 346:257-270.
80. Goadsby P.J., Hoskin K.L., Storer R.J., et al. Adenosine A(1) receptor agonists inhibit trigeminovascular nociceptive transmission. Brain 2002, 125:1392-1401.
81. Goadsby P.J., Ferrari M.D., Csanyi A., et al. Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis. Cephalalgia 2009, 29:742-750.
82. Gogas K.R. Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr Opin Pharmacol 2006, 6:68-74.
83. Gursoy-Ozdemir Y., Qiu J., Mastuoka N., et al. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 2004, 113:1447-1455.
84. Hamel E., Fan E., Linville D., et al. Expression of mRNA for the serotonin 5-hydroxytryptamine1D beta receptor subtype in human and bovine cerebral arteries. Mol Pharmacol 1993, 44:242-246.
85. Hargreaves R. New migraine and pain research. Headache 2007, 47:S26-S43.
86. Hargreaves R., Shepheard S. Pathophysiology of migraine - new insights. Can J Neurol Sci 1999, 26:S12-S19.
87. Harik S.I. Blood-brain barrier sodium/potassium pump: modulation by central noradrenergic innervation. Proc Natl Acad Sci U S A 1986, 83:4067-4070.
88. 2-mediated inflammatory pain sensitization. Science 2004, 304:884-887.
89. Henkes H., May A., Kühne D., et al. Sumatriptan: vasoactive effect on human dural vessels, demonstrated by subselective angiography. Cephalalgia 1996, 16:224-230.
90. 3H-5-hydroxytryptamine binding site subtype in bovine brain membranes. J Neurosci 1987, 7:894-903.
91. Hieble J.P. Subclassification and nomenclature of alpha- and beta-adrenoceptors. Curr Top Med Chem 2007, 7:129-134.
92. Hingtgen C.M., Vasko M.R. The phosphatase inhibitor, okadaic acid, increases peptide release from rat sensory neurons in culture. Neurosci Lett 1994, 178:135-138.
93. Hinz B., Cheremina O., Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J 2008, 22:383-390.
94. Honda M., Uchida K., Tanabe M., et al. Fluvoxamine, a selective serotonin reuptake inhibitor, exerts its antiallodynic effects on neuropathic pain in mice via 5-HT2A/2C receptors. Neuropharmacology 2006, 51:866-872.
95. Honey A.C., Bland-Ward P.A., Connor H.E., et al. Study of an adenosine A1 receptor agonist on trigeminally evoked dural blood vessel dilation in the anaesthetized rat. Cephalalgia 2002, 22:260-264.
96. Ho T.W., Ferrari M.D., Dodick D.W., et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008, 372:2115-2123.
97. Ho T.W., Mannix L.K., Fan X., et al. MK-0974 Protocol 004 study group. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008, 70:1304-1312.
98. Hoyer D., Middlemiss D.N. Species differences in the pharmacology of terminal 5-HT autoreceptors in mammalian brain. Trends Pharmacol Sci 1989, 10:130-132.
99. Hoyer D., Waeber C., Pazos A., et al. Identification of a 5-HT1 recognition site in human brain membranes different from 5-HT1A, 5-HT1B and 5-HT1C sites. Neurosci Lett 1988, 85:357-362.
100. Hoyer D., Hannon J.P., Martin G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002, 71:533-554.
101. Humphrey P. 5-Hydroxytryptamine and the pathophysiology of migraine. J Neurol 1991, 238:S38-S44.
102. Humphrey P., Feniuk W. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci 1991, 12:444-446.
103. Ichikawa H., Sugimoto T. VR1-immunoreactive primary sensory neurons in the rat trigeminal ganglion. Brain Res 2001, 890:184-188.
104. Ichikawa H., Sugimoto T. The co-expression of ASIC3 with calcitonin gene-related peptide and parvalbumin in the rat trigeminal ganglion. Brain Res 2002, 943:287-291.
105. Ichikawa H., Sugimoto T. The co-expression of P2X3 receptor with VR1 and VRL-1 in the rat trigeminal ganglion. Brain Res 2004, 998:130-135.
106. Iversen H.K. Human migraine models. Cephalalgia 2001, 21:781-785.
107. Iyengar S., Webster A.A., Hemrick-Luecke S.K., et al. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 2004, 311:576-584.
108. Jansen-Olesen I., Mortensen A., Edvinsson L., et al. Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase. Cephalalgia 1996, 16:310-316.
109. Jenkins D.W., Feniuk W., Humphrey P.P. Characterization of the prostanoid receptor types involved in mediating calcitonin gene-related peptide release from cultured rat trigeminal neurones. Br J Pharmacol 2001, 134:1296-1302.
110. Jenkins D., Langmead C., Parsons A.A., et al. Regulation of calcitonin gene-related peptide release from rat trigeminal nucleus caudalis slices in vitro. Neurosci Lett 2004, 366:241-244.
111. Johnson K., Bolay H. Neurogenic inflammatory mechanisms in migraine. The Headaches 2006, 309-319. Lippincott Williams & Wilkins, Philadelphia. 3rd edn. J. Olesen, P. Goadsby, N. Ramadan (Eds.).
112. Johnson K., Schaus J., Durkin M.M., et al. 5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. Neuroreport 1997, 8:2237-2240.
113. Johnson K.W., Phebus L.A., Cohen M.L. Serotonin in migraine: theories, animal models and emerging therapies. Prog Drug Res 1998, 51:219-244.
114. Jurna I., Brune K. Central effect of the non-steroid anti-inflammatory agents, indomethacin, ibuprofen, and diclofenac, determined in C fibre-evoked activity in single neurones of the rat thalamus. Pain 1990, 41:71-80.
115. Kamei D., Yamakawa K., Takegoshi Y., et al. Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin E synthase-1. J Biol Chem 2004, 279:33684-33695.
116. Kapoor K., Arulmani U., Heiligers J.P.C., et al. Effects of BIBN4096BS on cardiac output distribution and on CGRP-induced carotid haemodynamic responses in the pig. Eur J Pharmacol 2003, 475:69-77.
117. Katori M., Majima M. Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors. Inflamm Res 2000, 49:367-392.
118. Kaube H., Hoskin K.L., Goadsby P.J. Intravenous acetylsalicylic acid inhibits central trigeminal neurons in the dorsal horn of the upper cervical spinal cord in the cat. Headache 1993, 33:541-544.
119. Kennedy C.R., Zhang Y., Brandon S., et al. Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med 1999, 5:217-220.
120. Knight Y.E., Bartsch T., Kaube H., et al. P/Q-type calcium-channel blockade in the periaqueductal gray facilitates trigeminal nociception: a functional genetic link for migraine?. J Neurosci 2002, 22:RC213.
121. Knyihar-Csillik E., Tajti J., Csillik E.A., et al. Electrical stimulation of the Gasserian ganglion induces structural alterations of calcitonin gene-related peptide-immunoreactive perivascular sensory nerve terminals in the rat cerebral dura mater: a possible model of migraine headache. Neurosci Lett 1995, 184:189-192.
122. Kostrouchova M., Kostrouch Z., Kostrouchova M. Valproic acid, a molecular lead to multiple regulatory pathways. Folia Biol (Praha) 2007, 53:37-49.
123. Krishtal O. The ASICs: signaling molecules? Modulators?. Trends Neurosci 2003, 26:477-483.
124. Kroeze W.K., Kristiansen K., Roth B.L. Molecular biology of serotonin receptors structure and function at the molecular level. Curr Top Med Chem 2002, 2:507-528.
125. Leach M.J., Marden C.M., Miller A.A. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia 1986, 27:490-497.
126. Levy D., Jakubowski M., Burstein R. Disruption of communication between peripheral and central trigeminovascular neurons mediate the antimigraine action of 5HT1B/1D receptor agonists. Proc Natl Acad Sci U S A 2004, 101:4274-4279.
127. Levy D., Burstein R., Strassman A.M. Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neurol 2005, 58:698-705.
128. Li S., Doub W., Tang Y., et al. Acetaminophen: antipyretic or hypothermic in mice? In either case, PGHS-1b (COX-3) is irrelevant. Prostaglandins Other Lipid Mediat 2008, 85:89-99.
129. Linde K., Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev 2: 2004, CD003225.
130. Lipton R.B., Pan J. Is migraine a progressive brain disease?. JAMA 2004, 28:493-494.
131. Longmore J., Dowson A., et al. Advances in migraine therapy - 5-HT receptor subtype-specific agonist drugs. Curr Opin CPNS Invest Drugs 1999, 1:39-53.
132. Longmore J., Shaw D., Smith D., et al. Differential distribution of 5HT1D- and 5HT1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs. Cephalalgia 1997, 17:833-842.
133. Luman W., Gray R. Adverse reactions associated with sumatriptan. Lancet 1993, 341:1091-1092.
134. MacLeod A., Street L., Reeve A.J., et al. Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents. J Med Chem 1997, 40:3501-3503.
135. Malick A., Burstein R. Peripheral and central sensitization during migraine. Funct Neurol 2000, 15:S28-S35.
136. Mallee J., Salvatore C., LeBourdelles B., et al. Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J Biol Chem 2002, 277:14294-14298.
137. Mathew N. Pathophysiology, epidemiology, and impact of migraine. Clin Cornerstone 2001, 4:1-17.
138. May A., Leone M., Afra J., et al. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. Eur J Neurol 2006, 13:1066-1077.
139. Mayberg M., Langer R.S., Zervas N.T., et al. Perivascular meningeal projections from cat trigeminal ganglia: possible pathway for vascular headaches in man. Science 1981, 213:228-230.
140. Mayberg M.R., Zervas N.T., Moskowitz M.A. Trigeminal projections to supratentorial pial and dural blood vessels in cats demonstrated by horseradish peroxidase histochemistry. J Comp Neurol 1984, 223:46-56.
141. McCormack K., Brune K. Dissociation between the antinociceptive and antiinflammatory drugs and the dissociation between their antiinflammatory and analgesic effects. Drugs 1994, 47:28-45.
142. McCulloch J., Uddman R., Kingman T.A., et al. Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc Natl Acad Sci U S A 1986, 83:5731-5735.
143. Meves H. The action of prostaglandins on ion channels. Curr Neuropharmacol 2006, 4:41-57.
144. Mir P., Alberca R., Navarro A., et al. Prophylactic treatment of episodic cluster headache with intravenous bolus of methylprednisolone. Neurol Sci 2003, 24:318-321.
145. Moja P.L., Cusi C., Sterzi R.R., et al. Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev 2005, 3. CD002919.
146. Moreno M., Cohen Z., Stanimirovic D.B., et al. Functional calcitonin gene-related peptide type 1 and adrenomedullin receptors in human trigeminal ganglia, brain vessels, and cerebromicrovascular or astroglial cells in culture. J Cereb Blood Flow Metab 1999, 19:1270-1278.
147. Moreno M., Abounader R., Lantin S., et al. Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: potential implications in acute migraine treatment. Neuropharmacology 2002, 42:568-576.
148. Moreno M., Terron J., Stanimirovic D., et al. Characterization of calcitonin gene-related peptide (CGRP) receptors and their receptor-activity-modifying proteins (ramps) in human brain microvascular and astroglial cells in culture. Neuropharmacology 2002, 42:270-280.
149. Moriyama T., Higashi T., Togashi K., et al. Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins. Mol Pain 2005, 1:3.
150. Morteau O. Prostaglandins and inflammation: the cyclooxygenase controversy. Arch Immunol Ther Exp 2000, 48:473-480.
151. Moskowitz M.A. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992, 13:307-311.
152. Moskowitz M.A. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 1993, 43(Suppl. 3):S16-S20.
153. Moskowitz M.A., Bolay H., Dalkara T. Deciphering migraine mechanisms: clues from familial hemiplegic migraine genotypes. Ann Neurol 2004, 55:276-280.
154. Mueller L., Gallagher R., Ciervo C.A., et al. Vasospasm-induced mycocardial infarction with sumatriptan. Headache 1996, 36:329-331.
155. Mulderry P., Ghatei M., Spokes R.A., et al. Differential expression of alpha-CGRP and beta-CGRP by primary sensory neurons and enteric autonomic neurons of the rat. Neuroscience 1988, 25:195-205.
156. 2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 2000, 275:32783-32792.
157. 2 receptor antagonists and migraine therapy. J Neurol 1991, 238(Suppl. 1):S45-S52.
158. Narumiya S., Sugimoto Y., Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999, 79:1193-1226.
159. Negishi M., Sugimoto Y., Ichikawa A. Molecular mechanisms of diverse actions of prostanoid receptors. Biochim Biophys Acta 1995, 1259:109-119.
160. Nelson D.L., Gehlert D.R. Central nervous system biogenic amine targets for control of appetite and energy expenditure. Endocrine 2006, 29:49-60.
161. North R.A. The P2X3 subunit: a molecular target in pain therapeutics. Curr Opin Investig Drugs 2003, 4:833-840.
162. Nozaki K., Boccalini P., Moskowitz M.A., et al. Expression of c-fos-like immunoreactivity in brainstem after meningeal irritation by blood in the subarachnoid space. Neuroscience 1992, 49:669-680.
163. O'Banion M.K. Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Crit Rev Neurobiol 1999, 13:45-82.
164. O'Conner T., Van der Kooy D. Enrichment of a vasoactive neuropeptide (calcitonin gene related peptide) in the trigeminal sensory projection to the intracranial arteries. J Neurosci 1988, 8:2468-2476.
165. O'Neill G.P., Ford-Hutchinson A.W. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993, 330:156-160.
166. Ocana M., Cendan C.M., Cobos E.J., et al. Potassium channels and pain: present realities and future opportunities. Eur J Pharmacol 2004, 500:203-219.
167. Olesen J., Jansen-Olesen I. Nitric oxide mechanisms in migraine. Pathol Biol (Paris) 2000, 48:648-657.
168. Olesen J., Thomsen L.L., Iversen H. Nitric oxide is a key molecule in migraine and other vascular headaches. Trends Pharmacol Sci 1994, 15:149-153.
169. Olesen J., Diener H., Husstedt I.W., et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004, 350:1104-1110.
170. Oliver K.R., Wainwright A., Edvinsson L., et al. Immunohistochemical localization of calcitonin receptor-like receptor and receptor activity-modifying proteins in the human cerebral vasculature. J Cereb Blood Flow Metab 2002, 22:620-629.
171. Ophoff R.A., Terwindt G.M., Vergouwe M.N., et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the calcium channel gene CACNL1A4. Cell 1996, 87:543-552.
172. Ottervanger J., van Witsen T., Valkenburg H.A., et al. Adverse reactions attributed to sumatriptan. A postmarketing study in general practice. Eur J Clin Pharmacol 1994, 47:305-309.
173. Ottosson A., Edvinsson L. Release of histamine from dural mast cells by substance P and calcitonin gene-related peptide. Cephalalgia 1997, 17:166-174.
174. Owen S.F., Giltrow E., Huggett D.B., et al. Comparative physiology, pharmacology and toxicology of beta-blockers: mammals versus fish. Aquat Toxicol 2007, 82:145-162.
175. Ozyalcin S.N., Talu G.K., Kiziltan E., et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005, 45:144-152.
176. Paone D., Shaw A., Nguyen D., et al. Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide (MK-0974). J Med Chem 2007, 50:5564-5567.
177. Parsons A.A., Bingham S., Raval P., et al. Tonabersat (SB-220453) a novel benzopyran with anticonvulsant properties attenuates trigeminal nerve-induced neurovascular reflexes. Br J Pharmacol 2001, 132:1549-1557.
178. Paudel K.R., Das B.P., Rauniar G.P., et al. Antinociceptive effect of amitriptyline in mice of acute pain models. Indian J Exp Biol 2007, 45:529-531.
179. Peatfield R.C., Gawel M.J., Rose F.C. The effect of infused prostacyclin in migraine and cluster headache. Headache 1981, 21:190-195.
180. Pedigo N., Schoemaker H., Morelli M., et al. Benzodiazepine receptor binding in young, mature and senescent rat brain and kidney. Neurobiol Aging 1981, 2:83-88.
181. Peretz A., Degani N., Nachman R., et al. Meclofenamic acid and diclofenac, novel templates of KCNQ2/Q3 potassium channel openers, depress cortical neuron activity and exhibit anticonvulsant properties. Mol Pharmacol 2005, 67:1053-1066.
182. Pietrobon D. Migraine: new molecular mechanisms. Neuroscientist 2005, 11:373-386.
183. Poyner D., Sexton P., Marshall I., et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 2002, 54:233-246.
184. Prior M.J., Cooper K.M., May L.G., et al. Efficacy and safety of acetaminophen and naproxen in the treatment of tension-type headache. A randomized, double-blind, placebo-controlled trial. Cephalalgia 2002, 22:740-748.
185. 2+ channels and neurotransmitter release at the terminal of a mouse cortical neuron. J Neurosci 2001, 21:3721-3728.
186. Quirion R., Van Rossum D., Dumont Y., et al. Characterization of CGRP1 and CGRP2 receptor subtypes. Ann N Y Acad Sci 1992, 657:88-105.
187. Rao V.R., Finkbeiner S. NMDA and AMPA receptors: old channels, new tricks. Trends Neurosci 2007, 30:284-291.
188. Ray B.S., Wolff H.G. Experimental studies on headache: pain-sensitive structures of the head and their significance in headache. Arch Surg 1940, 41:813-856.
189. Reinold H., Ahmadi S., Depner U.B., et al. Spinal inflammatory hyperalgesia is mediated by prostaglandin E receptors of the EP2 subtype. J Clin Invest 2005, 115:673-679.
190. Reuter U., Bolay H., Jansen-Olesen I., et al. Delayed inflammation in rat meninges: implications for migraine pathophysiology. Brain 2001, 124:2490-2502.
191. Reuter U., Chiarugi A., Bolay H., et al. Nuclear factor-kappaB as a molecular target for migraine therapy. Ann Neurol 2002, 51:507-516.
192. Rist B., Lacroix J., Entzeroth M., et al. CGRP 27-37 analogues with high affinity to the CGRP1 receptor show antagonistic properties in a rat blood flow assay. Regul Pept 1999, 79:153-158.
193. Rosenfeld M., Mermod J.J., Amara S.G., et al. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature 1983, 304:129-135.
194. Rotondo D., Davidson J. Prostaglandin and PPAR control of immune cell function. Immunology 2002, 105:20-22.
195. Salvatore C., Hershey J., Corcoran H., et al. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan -3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J Pharmacol Exp Ther 2008, 324:416-421.
196. Samad T.A., Moore K.A., Sapirstein A., et al. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 2001, 410:471-475.
197. Samad T.A., Sapirstein A., Woolf C.J. Prostanoids and pain: unraveling mechanisms and revealing therapeutic targets. Trends Mol Med 2002, 8:390-396.
198. Saper J., Silberstein S. Pharmacology of dihydroergotamine and evidence for the efficacy and safety in migraine. Headache 2006, 46:S171-S181.
199. Saper J.R., Silberstein S.D., Lake A.E., et al. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache 1994, 34:497-502.
200. Sarchielli P., Alberti A., Codini M., et al. Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia 2000, 20:907-918.
201. Scatton B. The NMDA receptor complex. Fundam Clin Pharmacol 1993, 7:389-400.
202. Schrader H., Stovner L.J., Helde G., et al. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 2001, 322:19-22.
203. Schwab J.M., Brechtel K., Nguyen T.D., et al. Persistent accumulation of cyclooxygenase-1 (COX-1) expressing microglia/macrophages and upregulation by endothelium following spinal cord injury. J Neuroimmunol 2000, 111:122-130.
204. Schwab J.M., Schluesener H.J., Meyermann R., et al. COX-3 the enzyme and the concept: steps towards highly specialized pathways and precision therapeutics?. Prostaglandins Leukot Essent Fatty Acids 2003, 69:339-343.
205. Shanks R.G. Clinical pharmacology of vasodilatory beta-blocking drugs. Am Heart J 1991, 121:1006-1011.
206. Shepheard S., Williamson D., Williams J., et al. Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of rats. Neuropharmacology 1995, 34:255-261.
207. Shields K.G., Goadsby P.J. Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine?. Brain 2005, 128:86-97.
208. Shin J., Johnson J.A. Pharmacogenetics of beta-blockers. Pharmacotherapy 2007, 27:874-887.
209. Silberstein S.D. Methysergide. Cephalalgia 1998, 18:421-435.
210. Silberstein S., Tepper S., Brandes J., et al. Randomized, placebo-controlled trial of rofecoxib in the acute treatment of migraine. Neurology 2004, 62:1552-1557.
211. Simeone T.A., Wilcox K.S., White H.S. Subunit selectivity of topiramate modulation of heteromeric GABA(A) receptors. Neuropharmacology 2006, 50:845-857.
212. Singh V.P., Jain N.K., Kulkarni S.K. On the antinociceptive effect of fluoxetine, a selective serotonin reuptake inhibitor. Brain Res 2001, 915:218-226.
213. Smith M.I., Read S.J., Chan W.N., et al. Repetitive cortical spreading depression in a gyrencephalic feline brain: inhibition by the novel benzoylamino-benzopyran SB-220453. Cephalalgia 2000, 20:546-553.
214. Smith W.L., DeWitt D.L., Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000, 69:145-182.
215. Solomon D.H., Schneeweiss S., Glynn R.J., et al. Relationship between selective cyclooxygenase-2 inhibitors and myocardial infarction in older adults. Circulation 2004, 109:2068-2073.
216. Southall M.D., Vasco M.R. Prostaglandin receptor subtypes, EP3C and EP4, mediate the prostaglandin E-2-induced cAMP production and sensitization of sensory neurons. J Biol Chem 2001, 276:16083-16091.
217. Spierings G. Abortive treatment of migraine headache with non-inhaled, intranasal carbon dioxide: a randomized, double-blind, placebo-controlled, parallel-group study. Headache 2005, 45:809.
218. +-channel blockade in trigeminal root ganglion neurons: effects on membrane outward currents. J Neurophysiol 1989, 62:802-809.
219. Steenbergh P., Hoppener J., Zandberg J., et al. A second human calcitonin/CGRP gene. FEBS Lett 1985, 183:403-407.
220. Storer R.J., Goadsby P.J. Topiramate inhibits trigeminovascular neurons in the cat. Cephalalgia 2004, 24:1049-1056.
221. Strader C.D., Sigal I.S., Dixon R.A. Structural basis of beta-adrenergic receptor function. FASEB J 1989, 3:1825-1832.
222. Strassman A.M., Raymond S.A., Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996, 384:560-564.
223. Sugimoto Y., Narumiya S. Prostaglandin E receptors. J Biol Chem 2007, 282:11613-11617.
224. Suzuki K., Araki H., Mizoguchi H., et al. Prostaglandin E inhibits indomethacin-induced gastric lesions through EP-1 receptors. Digestion 2001, 63:92-101.
225. Takeda M., Tanimoto T., Ikeda M., et al. Activation of GABAB receptor inhibits the excitability of rat small diameter trigeminal root ganglion neurons. Neuroscience 2004, 123:491-505.
226. Tegeder I., Geisslinger G. Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences? Naunyn Schmiedebergs Arch. Pharmacol 2006, 373:1-17.
227. Tegeder I., Niederberger E., Vetter G., et al. Effects of selective COX-1 and -2 inhibition on formalin-evoked nociceptive behaviour and prostaglandin E(2) release in the spinal cord. J Neurochem 2001, 79:777-786.
228. Tfelt-Hansen P., Rolan P. Beta-adrenoceptor blocking drugs in migraine prophylaxis. The Headaches 2006, 519-528. Lippincott Williams & Wilkins, Philadelphia. 3rd edn. J. Olesen, P. Goadsby, N. Ramadan (Eds.).
229. Thalakoti S., Patil V., Damodaram S., et al. Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache 2007, 47:1008-1023.
230. Tronvik E., Stovner L.J., Helde G., et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 2003, 289:65-69.
231. Tsuboi K., Sugimoto Y., Ichikawa A. Prostanoid receptor subtypes. Prostaglandins Other Lipid Mediat 2002, 68-69:535-556.
232. Van der Kuy P.H., Lohman J.J. The role of nitric oxide in vascular headache. Pharm World Sci 2003, 25:146-151.
233. Van Rossum D., Hanisch U., Quirion R., et al. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev 1997, 21:649-678.
234. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin like drugs. Nat New Biol 1971, 231:232-235.
235. Vasco M.R., Campbell W.B., Waite K.J. Prostaglandin E(2) enhances bradykinin-stimulated release of neuropeptides from rat sensory neurons in culture. J Neurosci 1994, 14:4987-4997.
236. Vause C., Bowen E., Spierings E., et al. Effect of carbon dioxide on calcitonin gene-related peptide secretion from trigeminal neurons. Headache 2007, 47:1385-1397.
237. Vikelis M., Mitsikostas D.D. The role of glutamate and its receptors in migraine. CNS Neurol Disord Drug Targets 2007, 6:251-257.
238. V1.8 sodium channel in the maintenance of chronic inflammatory hypernociception. Neurosci Lett 2005, 386:72-77.
239. Visser W., Jaspers N., de Vriend R.H., et al. Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients. Cephalalgia 1996, 16:554-559.
240. Voilley N., de Weille J., Mamet J., et al. Nonsteroid anti-inflammatory drugs inhibit both the activity and the inflammation-induced expression of acid-sensing ion channels in nociceptors. J Neurosci 2001, 21:8026-8033.
241. Waxman S.G., Dib-Hajj S., Cummins T.R., et al. Sodium channels and pain. Proc Natl Acad Sci U S A 1999, 96:7635-7639.
242. Weizman R., Getslev V., Pankova I.A., et al. Pharmacological interaction of the calcium channel blockers verapamil and flunarizine with the opioid system. Brain Res 1999, 818:187-195.
243. Welch K.M. Brain hyperexcitability: the basis for antiepileptic drugs in migraine prevention. Headache 2005, 45(Suppl. 1):S25-S32.
244. Wermeling D.P. Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain. Pharmacotherapy 2005, 25:1084-1094.
245. Wess J. G-protein-coupled receptors: molecular mechanisms involved in receptor activation and selectivity of G-protein recognition. FASEB J 1997, 11:346-354.
246. Williamson D., Hill R., Goadsby P.J., et al. The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs. Br J Pharmacol 2001, 133:1029-1034.
247. Winner P., Ricalde O., Le Force B., et al. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996, 53:180-184.
248. Woolf C.J., Salter M.W. Neuronal plasticity: increasing the gain in pain. Science 2000, 288:1765-1769.
249. 2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. J Neurosci 2001, 21:5847-5853.
250. Zagami A., Goadsby P., Edvinsson L., et al. Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides 1990, 16:69-75.
251. Zeilhofer H.U. Prostanoids in nociception and pain. Biochem Pharmacol 2007, 73:165-174.
252. Zeilhofer H.U., Brune K. Analgesic strategies beyond the inhibition of cyclooxygenases. Trends Pharmacol Sci 2006, 27:467-474.
253. Zgombick J., Borden L., Cochran T.L., et al. Dual coupling of cloned human 5-hydroxytryptamine1D alpha and 5-hydroxytryptamine1D beta receptors stably expressed in murine fibroblasts: inhibition of adenylate cyclase and elevation of intracelluar calcium concentrations via pertussis toxin-sensitive G protein(s). Mol Pharmacol 1993, 44:575-582.
254. Zhang Z., Winborn C., Marquez de Prado B., et al. Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J Neurosci 2007, 27:2693-2703.
255. Zhu D.N., Moriguchi A., Mikami H., et al. Central amino acids mediate cardiovascular response to angiotensin II in the rat. Brain Res Bull 1998, 45:189-197.
256. Zissis N.P., Harmoussi S., Vlaikidis N., et al. A randomized, double-blind, placebo-controlled study of venlafaxine XR in out-patients with tension-type headache. Cephalalgia 2007, 27:315-324.